Improvements in survival from cancer have led to a large population who are at risk of late complications of chemotherapy. One of the most serious cardiovascular complications is chemotherapy-related cardiomyopathy (CRC), which may become clinically overt years or even decades after treatment and has over threefold higher mortality rate compared with idiopathic dilated cardiomyopathy. The early stages of this condition appear to respond well to cardioprotective medications (i.e. angiotensin-converting enzyme inhibitors, β-blockers). Periodic cardiac monitoring is necessary in this population to identify patients who would benefit from treatment. Cardio-oncology clinics have been established in recognition of this hazard in survivorship. This review summarises the epidemiology and pathophysiology of CRC, the evidence base for different non-invasive imaging modalities for screening and diagnosis and the rationale for treatment.

Item Type:	Refereed Article
Keywords:	chemotherapy, LV dysfunction, cardiotoxicity, echocardiography, strain imaging
Research Division:	Biomedical and Clinical Sciences
Research Group:	Cardiovascular medicine and haematology
Research Field:	Cardiology (incl. cardiovascular diseases)
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Clinical health not elsewhere classified
UTAS Author:	Nolan, MT (Mr Mark Nolan)
UTAS Author:	Lowenthal, RM (Professor Ray Lowenthal)
UTAS Author:	Venn, A (Professor Alison Venn)
UTAS Author:	Marwick, TH (Professor Tom Marwick)
ID Code:	96293
Year Published:	2014
Web of Science® Times Cited:	12
Deposited By:	Menzies Institute for Medical Research
Deposited On:	2014-10-29
Last Modified:	2017-11-01
Downloads:	0